Abstract
Trace element levels in the circulation (blood, serum, plasma) are believed to play a role in the pathophysiologic processes of Alzheimer’s disease (AD); however, there is heterogeneity in the available findings. This study conducted a systematic review and meta-analysis of trace elements (including: copper (Cu), iron (Fe), zinc (Zn), selenium (Se), lead (Pb), cadmium (Cd), mercury (Hg), manganese (Mn), aluminum (Al), arsenic (As), and magnesium (Mg)) in AD patients and controls to assess the variation of trace elements in the circulation of AD patients. By systematically screening case–control studies on circulatory trace element levels in AD patients from 2000 to the present in the PubMed, Web of Science, and MEDLINE databases, 52 studies were included in the final meta-analysis. The results of the random-effects model showed significantly elevated circulatory levels of Cd (SMD = 0.79, 95% CI: 0.35, 1.24), Hg (SMD = 0.59, 95% CI: 0.03, 1.16), and Cu (SMD = 0.70, 95% CI: 0.37, 1.04) in AD patients, while levels of Fe (SMD = − 0.58, 95% CI: − 1.03, − 0.13), Se (SMD = − 0.53, 95% CI: − 0.85, − 0.21), and Zn (SMD = − 0.99, 95% CI: − 1.52, − 0.46) were significantly lower. The database formed in this study provides reliable population-based research evidence for exploring changes in circulating trace element levels in AD patients. Monitoring and stabilization of circulatory trace element levels in the elderly may be a potential preventive target for AD.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Alzheimer’s disease (AD) is a genetic and sporadic neurodegenerative disorder that typically manifests as amnestic cognitive impairment, irreversible progressive function, cognition, and behavior loss with symptoms such as amnesia, prosopagnosia, and aphasia, and is the most common type of dementia [58, 89]. Over 57.4 million people worldwide suffer from AD or other dementias, and this number is predicted to rise to 153 million by 2050 [76]. The etiology of AD is complex and difficult to determine. In addition to endogenous factors such as age, genetics, and disease history, there is growing evidence that environmental pollutants are linked to the development of AD [63, 73, 135]. Identifying and intervening early on controllable environmental risk factors is important for preventing and delaying the development of AD [106].
Trace elements, such as lead (Pb), mercury (Hg), cadmium (Cd), arsenic (As), etc., are known neurotoxicants that can cross the blood–brain barrier and accumulate in the central nervous system, causing endoplasmic reticulum stress, mitochondrial damage, neuroinflammation, and neuronal apoptosis, etc. [9, 38, 65], belonging to the environment of the toxins with significant potential hazards [6]. While some other trace elements (copper (Cu), iron (Fe), zinc (Zn), magnesium (Mg), etc.) often act as catalysts in enzyme systems and play important roles in maintaining normal neurophysiology, including the synthesis of neurotransmitters, participation in catalytic reactions, maintenance of mitochondrial function and stabilization of protein structures [64]. Overexposure and homeostatic perturbations of trace elements lead to over-deposition of amyloid β (Aβ), hyperphosphorylation of tau, neural signaling, and the generation of free radicals, which are closely linked to the development of neurodegenerative pathologies and AD [8, 74, 144]. However, there is heterogeneity in the results of population-based studies on trace elements and AD due to differences in study design, population characteristics, sample sizes, biomaterials, testing methods, and evaluation criteria [82, 90, 107, 146]. There is no conclusive evidence regarding the changes that occur to trace elements in the circulation of AD patients.
This study reviewed and evaluated circulatory (serum, plasma, and blood) trace element levels in AD patients, aiming to comprehensively and systematically assess the association between trace elements and AD in case–control studies through meta-analysis, and to provide a theoretical framework for the identification of environmental risk and protective factors for AD, as well as the formulation of preventive strategies to proactively address healthy aging.
Methods
Literature search and selection
A search of the PubMed, Web of Science, and MEDLINE databases was conducted to identify case–control studies on trace element levels of AD patients published between January 2000 and April 2023. The search formula was detailed in the Supplementary material 1. Two investigators (JHZ and MQ) conducted a preliminary independent screening of titles and abstracts in the search catalog based on the following exclusion criteria: 1. irrelevant studies; 2. animal or in vitro cellular experiments; 3. systematic reviews, books and documents; 4. mechanistic studies. Articles that passed the initial screening were read in full, and studies meeting the following criteria were considered for inclusion: 1. A case–control study involving AD patients and healthy controls; 2. Patients met the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA), the National Institute on Aging—Alzheimer’s Association (NIA-AA), the International Classification of Diseases-10 (ICD-10), the Diagnostic and Statistical Manual Fourth Edition criteria (DSM-4), or the Mini-mental state examination (MMSE) criteria for AD, or confirmed AD patients explicitly stated in the study. 3. Detects trace element concentrations in whole blood, plasma, or serum; 4. Contains complete extractable data. Consensus between two authors, with a third author (YQ) negotiating in case of disagreement. Where multiple publications on the same population existed, only the report with the most comprehensive data was included. Figure 1 illustrates the screening process.
Data extraction and quality assessment
Two authors (XFL and XYX) independently evaluated each eligible study and extracted the following data: 1. first author’s name; 2. publication year; 3. study country; 4. element type; 5. type of biological samples; 6. sample size of AD and healthy groups; 7. percentage of females in groups; 8. mean age; 9. the mean and standard deviation of the trace element concentrations; 10. diagnostic criteria for AD; 11. detection method. All units were converted to μg/L due to differences in the underlying units of measurement among the studies.
Newcastle–Ottawa Quality Assessment Scale (NOS) was used to evaluate the quality of the included studies. Based on the “star system”, included studies are evaluated from three broad aspects: selection of study participants, comparability between case and control groups, exposure factors [145]. Studies scored (0–3) as low, (4–6) as moderate, and (7–9) as high quality.
Data analysis
Meta-analyses were performed using the STATA (version 17.0) software. The heterogeneity between studies was assessed using Chi-square and I-square tests. Statistical heterogeneity was defined as a p-value less than 0.10 or an I2 statistic greater than 50%, and a random effects model was used to combine the results of multiple studies. Conversely, a fixed effects model was employed. The pooled standardized mean difference (SMD) represents the difference in means across individual studies and serves as the summary statistic. A subgroup analysis based on sample type was conducted to evaluate the impact of study characteristics as a potential source of heterogeneity. Sensitivity analyses were carried out to assess the impact of individual studies on the pooled SMD. Egger’s test and funnel plots were utilized to evaluate publication bias. The forest plots were drawn to visualize SMDs and 95% confidence intervals (CIs), and results were considered statistically significant when the p-value was less than 0.05.
Results and discussion
Basic characteristics of included studies
There were 52 case–control studies of circulating trace elements in relation to AD that were included in this study. Eleven elements were analyzed in the included studies: copper (Cu, 30 studies), iron (Fe, 19 studies), zinc (Zn, 17 studies), selenium (Se, 16 studies), lead (Pb, 11 studies), cadmium (Cd, 10 studies), mercury (Hg, 8 studies), manganese (Mn, 7 studies), aluminum (Al, 6 studies), arsenic (As, 4 studies), and magnesium (Mg, 4 studies). Table 1 summarizes the main characteristics of the publications included. Two investigators (YQ and YYL) assessed the quality of all included studies in the meta-analysis using the NOS. The overall quality of the studies was favorable (Table 1). The study population came from countries such as Italy (30.8%), the United States (9.6%), India (9.6%), South Korea (7.7%), Australia (7.7%), China (5.8%), and others (Fig. 2A). Of the included studies, 80.8% used the NINCDS-ADRDA as the diagnostic criterion for AD, and the remainder used NIA-AA (3.8%), DSM-4 (3.8%), MMSE (1.9%), and ICD-10 (1.9%) (Fig. 2B). Five detection techniques were used: Inductively coupled plasma-Mass Spectrometry (ICP-MS, 40.4%), atomic absorption spectrometry (AAS, 38.5%), colorimetric assay (CA, 15.4%), total Reflection X-Ray Fluorescence (TXRF, 1.9%), and inductively coupled plasma optical emission spectroscopy (ICP-OES, 1.9%) (Fig. 2C).
Meta-analysis results
Cd levels in AD patients and controls
Ten studies compared Cd levels in the circulation of AD patients and controls. The combined sample size was 7522, consisting of 710 AD patients and 6812 healthy controls. Random effects model analysis showed that Cd levels were significantly higher in AD patients, with an SMD of 0.79 (95% CI 0.35, 1.24, p < 0.01). Subgroup analysis indicated that serum Cd levels were elevated in AD patients (SMD = 1.50, 95% CI 0.51, 2.48, p < 0.01). Figure 3A shows the forest plot of the SMD of Cd levels in AD patients and controls.
Cd is a toxic, non-essential transitional heavy metal that is widespread in the environment and enters the body mainly through diet and smoking, with a half-life of about 25–30 years in the human body [42]. Several adverse effects associated with Cd exposure have been demonstrated, including renal tubular damage, impaired glomerular reabsorption, long bone fractures, and decreased bone density [91, 92]. A growing body of research has also identified the neurotoxicity of Cd exposure to the brain as a potential contributing factor to cognitive decline [70]. Bypassing the blood–brain barrier, Cd can enter the central nervous system via epithelial transport in the olfactory nervous system, inducing oxidative stress and leading to neuroinflammation and neuronal death [19]. Additionally, Cd may exacerbate neurodegeneration by altering the permeability of the choroid plexus, causing Aβ aggregation and tau neurofibrillary tangles [79]. Studies in animal models have shown that brain structures of rats exposed to Cd salts have increased acetylcholinesterase activity and exhibit cognitive impairment and anxious behavior [46]. Furthermore, learning and memory deficits caused by Cd exposure may be due to the inhibition of α-secretase, which facilitates the production of Aβ protein precursors, leading to the accumulation of Aβ and senile plaques [112]. Cd also interferes with the metabolism of other essential metals in the cell. Cd exposure disrupts intracellular calcium (Ca) homeostasis and increases extracellular Ca influx, which triggers neuronal apoptosis by activating mitogen-activated protein kinase and mammalian target of rapamycin pathways [30]. Several population studies have also confirmed the association between Cd exposure and low cognitive function [32, 66]. A cross-sectional study of 2,068 adults over the age of 60 based on the National Health and Nutrition Examination Survey in the United States found that elevated blood levels of Cd were associated with cognitive impairment [66]. A prospective cohort study in China, which followed 1554 participants for three years, found similar results and found that the higher the level of Cd in the blood, the more pronounced the cognitive decline [70]. In our study, serum Cd levels changed significantly in AD patients, while blood Cd levels remained stable. This cannot be ruled out because of the small sample size, which included only five studies on blood Cd. In addition, blood Cd represents a recent exposure level that fluctuates widely depending on the environment, diet, and smoking, and further prospective cohort studies and clinical trials are needed to confirm this.
Hg levels in AD patients and controls
Eight studies comparing serum and blood Hg levels in AD patients and healthy controls were included, comprising a total of 669 AD patients and 839 controls. The results of the random effects model showed that AD patients had higher Hg levels than healthy controls, with a pooled SMD (95% CI) of 0.59 (0.03, 1.16) (p < 0.01). In the biomaterial subgroup, serum Hg levels were significantly elevated in the AD groups (SMD = 1.49, 95% CI 0.30, 2.68, p < 0.01). Figure 3B shows a forest plot of the SMD of Hg levels in AD patients and controls stratified by biomaterial.
Hg exists in three forms: monomeric, inorganic, and organic (methylmercury and ethylmercury). Volcanic eruptions and anthropogenic activities (ore mining, coal burning, metal smelting, waste incineration, etc.) are the main sources of Hg in the environment [27]. The mechanism of Hg neurotoxicity is complex because Hg vapor can cross the blood–brain barrier and lipid cell membranes and accumulate in inorganic forms in cells, triggering oxidative stress and leading to cytotoxicity and apoptosis [4]. Inorganic Hg has a long half-life in the brain, especially in the thalamus and pituitary [28], and inhibits β-microtubulin, which in turn disrupts the dynamic balance and biochemical homeostasis within neurons [29]. Methylmercury can cross the blood–brain and placental barriers and accumulate for long periods in the thalamus and pituitary, reducing choline uptake in the cerebral cortex, cerebellum, hippocampus, and brainstem. This leads to a decrease in the raw material for the synthesis of acetylcholine and affects the metabolism of neurotransmitters, causing clinical symptoms such as psychiatric and behavioral disorders, sensory abnormalities, ataxia, mental retardation, and speech and hearing disorders [27]. Studies in cell cultures, animal models, and AD patients have found a relationship between Hg exposure and features of AD, such as elevated levels of Aβ40, Aβ42 and phosphorylation of tau protein in cerebrospinal fluid [27]. After 45 days of sustained exposure to mercuric chloride in rats, Hg was deposited in the brain parenchyma, triggering glutamatergic neurochemical dysfunction in the motor cortex and hippocampus, resulting in reduced spontaneous movement, learning and memory abilities [131]. Prolonged low-dose exposure to Hg produces neurotoxic symptoms such as tremors, unsteady gait, moodiness, distractibility, temporary memory impairment, slurred speech, decreased motor skills, sensory abnormalities, and reduced neural conduction [88]. In population studies, higher blood Hg levels have been associated with poorer cognitive scores and delayed recall [109, 143], and serum and cerebrospinal fluid Hg concentrations were significantly higher in AD patients [43, 146]. However, there have also been case–control studies of AD that found no significant differences in circulating Hg levels between the two groups [44, 86]. From a comprehensive analysis of the included studies, we conclude that the evidence for significantly elevated serum Hg levels in AD patients is reliable. Although blood Hg levels in AD patients were lower than in controls (SMD (95% CI) = − 0.19 (− 0.37, − 0.02)), there was no significant difference (p = 0.264), which cannot exclude an opposite trend due to differences in metabolism of the element in different biosample environments. Further validation is expected from additional biological samples and cohort studies.
Cu levels in AD patients and controls
Thirty studies have reported circulating levels of Cu in AD patients and controls. The combined sample size was 4303, with 2010 AD patients and 2293 controls. The results showed that circulating Cu levels were significantly higher in AD patients than in controls, and the pooled SMD (95% CI) was 0.70 (0.37, 1.04) (p < 0.01). Subgroup analyses showed that AD patients had significantly higher serum Cu levels than controls (SMD = 0.82, 95% CI 0.47, 1.16, p < 0.01), whereas blood and plasma Cu levels were not significantly different between the two groups. Figure 3C shows a forest plot of the SMD of Cu levels in AD patients and controls stratified by biomaterial.
Cu is an essential trace mineral that enters the body in inorganic form through drinking water and food, and is absorbed in the stomach and upper part of the small intestine, with the highest levels in the liver and brain [20, 50]. As an important transition metal, Cu is involved in a wide variety of redox reactions and is an essential cofactor for many catalytic enzymes [53]. Cu overload leads to the Fenton reaction and impairs mitochondrial function, generating reactive oxygen species (ROS) that disrupt macromolecular function and structure, leading to oxidative cell damage and death [54]. The majority of circulating Cu is synthesized in the liver as ceruloplasmin or bound to albumin or micronutrients (such as histidine and peptides), with the remaining small fraction (0.5–5.0%) of low molecular weight serum Cu defined as ultrafilterable Cu or free Cu [115, 120]. Free Cu readily crosses the blood–brain barrier and constitutes a “labile” Cu pool that may participate in the pathogenesis of AD by regulating the production, aggregation, and stabilization of amyloid in the form of protofibrils, and by promoting the aggregation and phosphorylation of tau induced by ROS or neuroinflammatory processes [104, 125]. Several clinical studies have demonstrated that elevated free Cu levels correlate with electroencephalographic-recorded brain activity, signs of cerebral atrophy, and Aβ and tau protein levels in pathologic cerebrospinal fluid [119, 148]. Studies in animal models have shown that amyloid plaques in AD have a high affinity for Cu, and that Cu dyshomeostasis leads to Aβ deposition in senile plaques and neuroprogenitor fiber tangles [140, 150]. In the brains of AD patients, Cu reduction produces H2O2 and toxic lipid oxidation products, leading to Aβ peptide oligomerization and accelerating plaque deposition and lipid peroxidation [80, 115]. Population-based studies have shown that AD patients exhibit significantly elevated serum Cu levels compared to controls [90, 100, 108, 146]. Furthermore, free Cu levels have been shown to reflect the duration and progression of brain disease, i.e., increased free Cu is often accompanied by deterioration in cognitive function, which is more pronounced in patients with dementia compared to those with mild cognitive impairment (MCI) [101, 116]. In addition, elevated serum free Cu levels increase the predisposition to AD by approximately threefold. Additionally, MCI patients with elevated free Cu levels have a threefold increased likelihood of converting to AD compared to MCI patients with normal free Cu levels [117]. This study shows that Cu levels in AD patients are markedly elevated in serum and remain stable in plasma and blood. Given the specific role of free Cu, it is crucial to conduct clinical studies on liver function in AD patients or utilize transgenic animal models to decipher the neurotoxic effects of Cu. Furthermore, longitudinal studies that encompass ceruloplasmin and free Cu interrelationships and imaging markers are essential to comprehend the role of Cu in AD progression.
Fe levels in AD patients and controls
A total of 19 studies compared serum and blood Fe levels in AD patients and controls, including 1,063 AD patients and 936 healthy controls. The results of the random effects model showed that circulating Fe levels were significantly lower in AD patients than in controls, with a pooled SMD (95% CI) of -0.58 (-1.03, -0.13) (p < 0.01). In the biomaterials subgroup, serum Fe levels were significantly reduced in AD patients (SMD = − 0.60, 95% CI − 1.09, − 0.10, p < 0.01), while blood Fe levels were unchanged. Figure 4A shows a forest plot of the SMD of Fe levels in AD patients and controls stratified by biomaterial.
Fe is one of the most abundant essential trace minerals in the human body and an important transition metal. Several studies have shown that disorders of Fe homeostasis are involved in the etiopathogenesis of several neurodegenerative diseases, including AD [24, 34]. In these patients, Fe accumulation in certain regions of the brain (i.e., basal ganglia, hippocampus, neocortex, as well as the senile plaques and neurofibrillary tangles) is greater than that found in healthy aging and is often associated with oxidative stress [34, 36, 142]. And Fe overload and reduced bioavailability in the brain have been shown to decrease catalase activity, impair neurotransmitter production, and lead to memory, cognitive, and motor dysfunction [139]. On the other hand, the major Fe transport system also transports heavy metals, and inadequate Fe stores in the body increase the expression of divalent metal transporter-1 in cerebral neurons and vascular endothelial cells, which affects the uptake of heavy metals by the epithelial cells and increases the burden of heavy metals in the body [84]. Additionally, alterations in Fe levels impact Cu transport across the brain barrier. For instance, a significant increase (+ 55%) in Cu levels was observed in the cerebrospinal fluid, brain parenchyma, and choroid plexus of an Fe-deficient rat model [7]. Furthermore, research has indicated that anemia and reduced hemoglobin levels are associated with an elevated risk of developing AD [40, 105]. In MCI and early stages of AD, relatively low peripheral Fe levels and underlying neuroinflammation lead to elevated serum ferritin, whereas in advanced stages of the disease, elevated serum ferritin and impaired blood–brain barrier integrity led to elevated serum Fe [56]. This suggests that changes in serum Fe levels in AD patients are not consistent across the different stages of the disease, which may also explain the heterogeneous results of some studies of circulating Fe levels in AD patients [56, 90]. According to our results, AD patients had lower serum Fe levels than controls, which is consistent with the results of two previous meta-analyses [47, 130]. However, future studies should focus on the changes and associations of elemental levels at different stages of AD.
Se levels in AD patients and controls
Sixteen studies have reported circulating Se levels in AD patients and controls, including 683 AD patients and 745 controls, for a total of 1,428 individuals. Random effects modeling results showed that circulating Se levels were significantly lower in AD patients than in controls, with a composite SMD of -0.53 (95% CI − 0.85, − 0.21, p < 0.01). Subgroup analyses revealed that plasma Se levels were significantly reduced in AD patients (SMD = -0.83, 95% CI − 1.05, − 0.62, p < 0.01), whereas serum and blood Se levels did not change significantly. Figure 4B shows a forest plot of the SMD of Se levels in AD patients and controls stratified by biomaterial.
It is well known that oxidative stress plays an important role in the development and progression of AD, as the brain has a high rate of oxygen consumption and a high content of polyunsaturated lipids, making it susceptible to lipid peroxidation and oxidative damage [52]. Se is an important micronutrient also an antioxidant that affects the activity and synthesis of antioxidant enzymes such as glutathione peroxidase, selenoprotein P, thioredoxin reductase, and methionine sulfoxide reductase B [16]. In a memory-impaired rat model, Se is a neuroprotective agent that delays neuronal degeneration by reducing lipid peroxidation and limiting the production of Aβ proteins [10]. Se is a component of glutathione peroxidase, an enzyme that catalyzes the redox reaction of reduced glutathione with peroxides to resist lipid peroxidation and hydrogen peroxide and protect the brain from oxidative damage [72]. Selenoprotein P, the major Se transporter protein in brain tissue, exerts antioxidant effects by reducing phospholipid hydroperoxidase and inhibiting low-density lipoprotein oxidation [103]. Selenoprotein P has also been found in senile plaques and neurogenic fiber tangles in the brains of AD patients, suggesting that it plays a crucial role in safeguarding neurons from oxidative stress [113]. Population studies have found significant differences in peripheral circulating Se concentrations in AD and MCI patients compared to controls [31, 75, 147]. A nine-year cohort study found that low Se levels were positively associated with cognitive decline in the elderly [2]. A possible explanation is that the brain has the highest Se metabolic priority, and plasma Se is readily depleted in the presence of MCI and AD, prioritizing the synthesis of selenoproteins and other antioxidants in the brain to protect polyunsaturated fatty acids in neuronal cell membranes [26]. Thus, the significantly lower plasma Se concentrations in AD and MCI patients may result from increased depletion of glutathione peroxidase and other Se-dependent antioxidants during the development of AD [31]. Considering that Se may act directly as an antioxidant or indirectly on AD progression by improving brain metabolism, monitoring Se levels in the peripheral circulation as well as dietary Se supplementation may be beneficial interventions to increase brain free radical defense to delay AD progression.
Zn levels in AD patients and controls
Seventeen studies compared circulating Zn levels in AD patients and controls, comprising 869 AD patients and 1309 healthy controls, for a total of 2178 individuals. Random-effects model analysis showed that circulating Zn levels were significantly lower in AD patients than in controls, with a pooled SMD (95% CI) of − 0.99 (− 1.52, − 0.46) (p < 0.01). Subgroup analyses revealed that serum Zn levels were significantly lower in AD patients (SMD = − 1.21, 95% CI − 1.83, − 0.60, p < 0.01), whereas plasma and blood Zn levels did not change significantly. Figure 4C shows a forest plot of the SMD of Zn levels in AD patients and controls stratified by biomaterial.
Zn is a redox inactive essential trace element involved in stabilizing protein structures and catalyzing reactions in living organisms and is critical for brain function [15]. Several aging studies have found that lower serum Zn levels in the elderly are associated with inflammatory processes, increased amyloid levels, and decreased memory and cognitive function [128]. The Zn enters the brain across the blood–brain and blood-cerebrospinal fluid barriers, and cerebral capillary endothelial cells respond to changes in systemic Zn status by increasing or decreasing Zn uptake [37]. It has been suggested that Zn deficiency may contribute to the development of AD. Zn levels in the brain of AD patients are positively associated with Aβ peptide levels, plaque count, and dementia severity [94]. Reduced peripheral circulating Zn levels in AD patients will result in increased Zn uptake by brain capillary epithelial cells to maintain Zn stores, and large brain Zn stores may increase Aβ adhesion and promote Aβ aggregation and plaque formation [33]. A clinical intervention study in AD patients confirmed elevated serum Zn levels in AD patients following treatment with the Zn-binding compound clioquinol, which inhibits the binding of Zn ions to Aβ, thereby facilitating Aβ solubilization and reducing its toxicity [98]. Zn also has antioxidant and anti-inflammatory properties, reducing free radical formation by antagonizing redox-active transition metals and protecting the sulfhydryl groups of proteins from free radical attack [55]. On the other hand, there is evidence that there is an antagonism between Zn and Cu absorption, with both competing for the same carrier proteins in intestinal mucosal cells [129]. In a double-blind study of elderly AD patients over the age of 70, supplementation with Zn was found to reduce blood levels of free Cu and prevent cognitive decline [23]. Most studies generally agree with the findings of this study that AD is associated with low serum Zn levels [18, 111, 139]. Certainly, this causal relationship needs to be further substantiated by prospective cohort studies. Given the clinical significance of Zn deficiency in the progression of AD, Zn intervention may be a possible therapeutic target [37].
Residual trace element levels in AD patients and controls
Forest plots of SMD in AD patients and controls stratified by biomaterial for Al, As, Mg, Mn and Pb are shown in Figures S1-S5. The results of the random effects model showed that circulating levels of these trace elements did not change significantly in AD patients compared to healthy controls. The pooled SMD (95% CI) were: Al: 0.67 (− 0.05, 1.38); As: 0.87 (− 0.14, 1.88); Mg: − 1.86 (− 3.82, 0.09); Mn: − 0.19 (− 0.61, 0.24); Pb: 0.03 (− 0.19, 0.25), respectively.
Al, the most abundant neurotoxic metal in the Earth's crust [126], accumulates semi-permanent manner in AD-susceptible neuronal foci via the blood–brain barrier and the intracellular transport pathway of transferrin, and is involved in the induction of oxidative stress, APP gene up-regulation, and amyloid-β conformational changes [35, 134]. Some studies have reported higher AD morbidity or mortality in areas with high Al exposure, suggesting that chronic Al exposure contributes to AD [99, 141]. However, some dissenting voices have argued that bioavailable Al cannot enter the brain in sufficient quantities to cause damage [132], and also that there is still a lack of clear explanations for lifelong exposure to Al as a significant risk factor for AD due to deficiencies in epidemiological study design [77].
As is neurotoxic and impairs cognitive and memory functions. Exposure to As and its metabolites leads to ROS formation, inflammation, mitochondrial dysfunction, and disruption of not only protein homeostasis but also Ca signaling [93]. In addition, As is a known cardiovascular toxicant [133]. The vascular hypothesis of AD suggests that AD is the result of vascular damage that reduces cerebral blood perfusion rates and thus indirectly damages neurons [137]. Studies have shown that environmental As levels are positively correlated with mortality from AD [69, 83]. However, our study did not find significant changes in circulating As levels in AD patients, which is consistent with the findings of others [67, 86]. This may be partly due to the small number of studies included, but also to the fact that As is absorbed by amyloid plaques, which consume As from other body compartments such as blood. Therefore, more severe AD with more plaques shows lower serum As levels [12].
Mg is the second most abundant intracellular divalent cation and a cofactor for more than 300 metabolic reactions in the body [138]. It is neuroprotective, interacting with the N-methyl-D-aspartate (NMDA) receptor and blocking Ca channel in the NMDA receptor, preventing oxidative stress and neuronal cell death due to excitotoxicity [57]. Mg is also involved in normal neuronal maturation, neuromuscular transmission and maintaining the integrity of the blood–brain barrier [11]. As the blood–brain barrier keeps the daily fluctuations of blood Mg in brain tissue at bay, cerebrospinal fluid seems to be a more representative biomaterial for the analysis of Mg homeostasis in AD patients [134]. A systematic review of Mg levels in AD patients found that Mg concentrations were significantly lower in cerebrospinal fluid and hair of AD patients, but no differences were observed in serum and plasma [136]. The study concluded that serum Mg is not a reliable marker of Mg status in the elderly.
Mn is an essential metal for maintaining homeostasis, a cofactor for important metalloenzymes that regulate oxidative stress and the glutamate/glutamine cycle [114], and supports neurotransmission, cellular metabolism, antioxidant defenses, and participates in inflammatory responses in the human body [68]. However, there are conflicting results regarding Mn levels in the plasma and cerebrospinal fluid of AD patients [13, 48, 61, 94]. Mn overexposure causes neurotoxicity, including disruption of mitochondrial function and neurotransmitter metabolism, altered Fe homeostasis, and oxidative stress [51]. Studies have shown that elevated Mn levels are associated with increased plasma levels of amyloid-like protein-1 and Aβ peptide, which are hallmarks of AD [134]. In addition, prolonged exposure to Mn can lead to the loss of neurons and glial cells in the brain. It may also cause the overproliferation of astrocytes, resulting in what is known as “AD astrocytosis” [78].
Pb has complex and numerous mechanisms of neurotoxicity and is a known neurotoxicant that causes non-specific brain damage. Approximately 95% of the human Pb burden is in bone, bone Pb has a half-life of 20–30 years, whereas the average turnover period for blood Pb is about 30 days, and circulating Pb levels are associated with acute exogenous exposures [49]. Pb binds to divalent metal transporter proteins, crosses the blood–brain barrier instead of Ca and accumulates in the brain [102]. Causes oxidative stress by depleting thiols and disrupting antioxidant defenses, leading to endoplasmic reticulum stress, mitochondrial damage, and neuronal apoptosis [102]. In animal models, Pb treatment induces pathological changes associated with AD, including Aβ accumulation, elevated levels of total and hyperphosphorylated tau, inflammation, and memory deficits [14, 41]. In older populations, Pb exposure is associated with lower cognitive status and longitudinal cognitive decline, but additional prospective evidence from human clinical samples is needed [9].
Publication bias
The funnel plot for elements was shown in Figure S6. Sensitivity analyses indicated that none of the studies significantly affected the aggregate results. Egger's test results were as follows: Cd (p = 0.009), publication bias existed; Cu (p = 0.165), no publication bias; Hg (p = 0.072), no publication bias; Fe (p = 0.709), no publication bias; Se (p = 0.500), no publication bias; Zn (p = 0.094), no publication bias; Al (p = 0.024), publication bias existed; As (p = 0.034), publication bias existed; Mg (p = 0.035), publication bias existed; Mn (p = 0.854), no publication bias; Pb (p = 0.654), no publication bias.
Uncertainties and limitations
The limitations and uncertainties of this study may arise from the following: First, results on Cd, Al, As, and Mg ought to be interpreted cautiously, as publication bias was found in the inclusion studies. This may be attributed to the small number of studies included or methodological differences. Further studies are expected to confirm our findings. Second, SMD cannot adjust for potential confounders, so we should be cautious about the combination of results. Third, different trace elements have different in vitro exposure pathways and in vivo metabolism [149]. Additional monitoring studies on other biological materials (e.g., urine, cerebrospinal fluid, nails, hair, etc.) are warranted. Fourth, the analytical results derived from cross-sectional and case–control studies in this study do not prove causality. Finally, due to limited published studies on other elements, this study only analyzed the levels of eleven elements in AD patients, and other elements should receive more attention in the future.
Conclusions
In conclusion, we performed a systematic meta-analysis of case–control studies of trace elements in the circulation of AD patients, and found that serum levels of Cd, Hg, and Cu were significantly elevated in AD patients, whereas serum Fe, Zn, and plasma Se were significantly lower than in controls. Due to limitations in the number of studies and biological materials, other trace elements that showed publication bias or results that were not significantly different or were not included in this study deserve more attention in the future. In addition, the vast majority of included studies used a cross-sectional design, and more in-depth prospective cohort studies of the longitudinal course of elemental exposure, as well as patients with pre-AD, are needed to identify and assess the causality between trace element levels and AD, and to weigh the potential influence of trace elements throughout the disease process.
Data availability
No datasets were generated or analysed during the current study.
References
Agarwal R et al (2008) Serum copper in Alzheimer’s disease and vascular dementia. Ind J Clin Biochem 23:369–374
Akbaraly NT et al (2007) Plasma selenium over time and cognitive decline in the elderly. Epidemiology 18:52–58
Alsadany MA et al (2013) Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen 28:54–61
Aragão WAB et al (2018) Hippocampal dysfunction provoked by mercury chloride exposure: evaluation of cognitive impairment, oxidative stress, tissue injury and nature of cell death. Oxid Med Cell Longev 2018:1–11
Ashraf A, et al. (2019) Pattern of Altered Plasma Elemental Phosphorus, Calcium, Zinc, and Iron in Alzheimer’s Disease. Scientific Reports. 9
ATSDR, Agency for Toxic Substances and Disease Registry. The ATSDR 2019 Substance Priority List. Department of Health and Human Services, Public Health Service. https://www.atsdr.cdc.gov/spl/#2019spl, Atlanta, GA: U.S., 2019.
Azhdarzadeh M et al (2013) Serum multivalent cationic pattern: speculation on the efficient approach for detection of Alzheimer’s disease. Sci Rep 3:2782
Babić Leko M et al (2022) Heavy metals and essential metals are associated with cerebrospinal fluid biomarkers of Alzheimer’s disease. Int J Mol Sci 24:467
Bakulski KM et al (2020) Heavy metals exposure and Alzheimer’s disease and related dementias. J Alzheimers Dis 76:1215–1242
Balaban H et al (2016) The protective role of selenium on scopolamine-induced memory impairment, oxidative stress, and apoptosis in aged rats: the involvement of TRPM2 and TRPV1 channels. Mol Neurobiol 54:2852–2868
Barbagallo M et al (2021) Magnesium in aging, health and diseases. Nutrients 13:1–20
Baum L et al (2010) Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability. Biometals 23:173–179
Beatrice B et al (2005) Development of methods for the quantification of essential and toxic elements in human biomonitoring. Annali Dell’Istituto Superiore di Sanita 41:165–170
Bihaqi SW et al (2014) Infantile postnatal exposure to lead (Pb) enhances tau expression in the cerebral cortex of aged mice: relevance to AD. Neurotoxicology 44:114–120
Bitanihirwe BKY, Cunningham MG (2009) Zinc: the brain’s dark horse. Synapse 63:1029–1049
Bjørklund G et al (2022) Selenium: an antioxidant with a critical role in anti-aging. Molecules 27:1–16
Bocca B et al (2006) Alterations in the level of trace metals in Alzheimer’s disease. Trace Elem Electrolytes 23:270–276
Bocca B et al (2005) Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer’s disease. Ann Ist Super Sanita 41:197–203
Bondier JR et al (2008) Harmful effects of cadmium on olfactory system in mice. Inhal Toxicol 20:1169–1177
Brewer G (2015) Copper-2 ingestion, plus increased meat eating leading to increased copper absorption, are major factors behind the current epidemic of Alzheimer’s disease. Nutrients 7:10053–10064
Brewer GJ et al (2010) Copper and ceruloplasmin abnormalities in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 25:490–497
Brewer GJ et al (2010) Subclinical zinc deficiency in Alzheimer’s disease and Parkinson’s disease. Am J Alzheimers Dis Other Demen 25:572–575
Brewer GJ, Kaur S (2013) Zinc deficiency and zinc therapy efficacy with reduction of serum free copper in Alzheimer’s disease. Int J Alzheimer Dis 2013:1–4
Bush AI et al (2012) The metal theory of Alzheimer’s disease. J Alzheimers Dis 33:S277–S281
Cardoso BR et al (2017) Selenium levels in serum, red blood cells, and cerebrospinal fluid of Alzheimer’s disease patients: a report from the Australian imaging, biomarker & lifestyle flagship study of ageing (AIBL). J Alzheimers Dis 57:183–193
Cardoso BR et al (2010) Nutritional status of selenium in Alzheimer’s disease patients. Br J Nutr 103:803–806
Cariccio VL et al (2019) Mercury involvement in neuronal damage and in neurodegenerative diseases. Biol Trace Elem Res 187:341–356
Ceccatelli S et al (2010) Methylmercury-induced neurotoxicity and apoptosis. Chem Biol Interact 188:301–308
Chan MC et al (2017) Inorganic mercury prevents the differentiation of SH-SY5Y cells: Amyloid precursor protein, microtubule associated proteins and ROS as potential targets. J Trace Elem Med Biol 41:119–128
Chen S et al (2011) CaMKII is involved in cadmium activation of MAPK and mTOR pathways leading to neuronal cell death. J Neurochem 119:1108–1118
Chmatalova Z et al (2017) Relation of plasma selenium and lipid peroxidation end products in patients with Alzheimer’s disease. Physiol Res 66:1049–1056
Ciesielski T et al (2013) Associations between cadmium exposure and neurocognitive test scores in a cross-sectional study of US adults. Environ Health 12:13
Craddock TJA et al (2012) The zinc dyshomeostasis hypothesis of Alzheimer’s disease. PLoS ONE 7:e33552
Crespo ÂC et al (2014) Genetic and biochemical markers in patients with Alzheimer’s disease support a concerted systemic iron homeostasis dysregulation. Neurobiol Aging 35:777–785
Dey M, Singh RK (2022) Neurotoxic effects of aluminium exposure as a potential risk factor for Alzheimer’s disease. Pharmacol Rep 74:439–450
Ding B et al (2009) Correlation of iron in the hippocampus with MMSE in patients with Alzheimer’s disease. J Magn Reson Imaging 29:793–798
Dong J et al (2008) Serum zinc in the progression of Alzheimer’s disease. J Alzheimers Dis 15:443–450
Dorea JG (2021) Neurodevelopment and exposure to neurotoxic metal(loid)s in environments polluted by mining, metal scrapping and smelters, and e-waste recycling in low and middle-income countries. Environ Res 197:1–11
Fathabadi B et al (2018) Comparison of blood lead levels in patients with alzheimer’s disease and healthy people. Am J Alzheimers Dis Other Demen 33:541–547
Faux NG et al (2014) An anemia of Alzheimer’s disease. Mol Psychiatry 19:1227–1234
Gąssowska M et al (2016) Perinatal exposure to lead (Pb) promotes Tau phosphorylation in the rat brain in a GSK-3β and CDK5 dependent manner: Relevance to neurological disorders. Toxicology 347–349:17–28
Genchi G et al (2020) The effects of cadmium toxicity. Int J Environ Res Public Health 17:3782–3806
Gerhardsson L et al (2008) Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 25:508–515
Giacoppo S et al (2014) Heavy metals and neurodegenerative diseases: an observational study. Biol Trace Elem Res 161:151–160
Giambattistelli F et al (2012) Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer’s disease. Neurobiol Aging 33:1633–1641
Gonçalves JF et al (2012) Behavior and brain enzymatic changes after long-term intoxication with cadmium salt or contaminated potatoes. Food Chem Toxicol 50:3709–3718
Gong L et al (2023) Levels of iron and iron-related proteins in Alzheimer’s disease: a systematic review and meta-analysis. J Trace Elem Med Biol 80:127304
Gonzalez-Dominguez R et al (2014) Characterization of metal profiles in serum during the progression of Alzheimer’s disease. Metallomics 6:292–300
Hare DJ et al (2016) Lead and manganese levels in serum and erythrocytes in Alzheimer’s disease and mild cognitive impairment: results from the Australian imaging, biomarkers and lifestyle flagship study of ageing. Metallomics 8:628–632
Hsu H-W et al (2018) Environmental and dietary exposure to copper and its cellular mechanisms linking to Alzheimer’s disease. Toxicol Sci 163:338–345
Huat TJ et al (2019) Metal toxicity links to Alzheimer’s disease and neuroinflammation. J Mol Biol 431:1843–1868
Ionescu-Tucker A, Cotman CW (2021) Emerging roles of oxidative stress in brain aging and Alzheimer’s disease. Neurobiol Aging 107:86–95
Itoh S et al (2009) Novel mechanism for regulation of extracellular SOD transcription and activity by copper: role of antioxidant-1. Free Radical Biol Med 46:95–104
Jiang D et al (2007) Redox reactions of copper complexes formed with different β-amyloid peptides and their neuropathalogical relevance. Biochemistry 46:9270–9282
Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283:65–87
Jouini N et al (2021) Impacts of iron metabolism dysregulation on Alzheimer’s disease. J Alzheimers Dis 80:1439–1450
Kirkland AE et al (2018) The role of magnesium in neurological disorders. Nutrients 10:1–23
Knopman DS et al (2021) Alzheimer disease. Nat Rev Dis Primers 7:33
Koc ER et al (2015) A comparison of hair and serum trace elements in patients with Alzheimer disease and healthy participants. Turk J Med Sci 45:1034–1039
Kweon OJ et al (2019) Clinical utility of serum hepcidin and iron profile measurements in Alzheimer’s disease. J Neurol Sci 403:85–91
Lavanya RD et al (2021) Trace element imbalances in blood serum of Alzheimer’s disease patients. Spectrosc Lett 54:458–471
Lee JY et al (2012) The association of heavy metal of blood and serum in the Alzheimer’s diseases. Toxicol Res 28:93–98
Legradi JB et al (2018) An ecotoxicological view on neurotoxicity assessment. Environ Sci Eur 30:1–34
Lei P et al (2021) The essential elements of Alzheimer’s disease. J Biol Chem 296:100105
Li B et al (2021) Astrocytes in heavy metal neurotoxicity and neurodegeneration. Brain Res 1752:1–13
Li H et al (2018) Associations between blood cadmium levels and cognitive function in a cross-sectional study of US adults aged 60 years or older. BMJ Open 8:1–14
Li K et al (2023) Trace elements and Alzheimer dementia in population-based studies: a bibliometric and meta-analysis. Environ Pollut 318:120782
Li L, Yang X (2018) The essential element manganese, oxidative stress, and metabolic diseases: links and interactions. Oxid Med Cell Longev 7580707:1–11
Li X et al (2020) Positive association between soil arsenic concentration and mortality from alzheimer’s disease in mainland China. J Trace Elem Med Biol 59:1–14
Liu H et al (2021) Higher blood cadmium level is associated with greater cognitive decline in rural Chinese adults aged 65 or older. Sci Total Environ 756:1–7
Lopez N et al (2013) Oxidative stress in Alzheimer’s disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33:823–829
Luo J et al (2022) Blood selenium and serum glutathione peroxidase levels were associated with serum β-amyloid in older adults. Biol Trace Elem Res 201:3679–3687
Ma Y-H et al (2023) Association of long-term exposure to ambient air pollution with cognitive decline and Alzheimer’s disease-related amyloidosis. Biol Psychiat 93:780–789
Mezzaroba L et al (2019) The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology 74:230–241
Nascimento CQD et al (2021) Selenium concentrations in elderly people with Alzheimer’s disease: a cross-sectional study with control group. Rev Bras Enferm 74(Suppl2):e20200984
Nichols E et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health 7:e105–e125
Nie J (2018) Exposure to aluminum in daily life and Alzheimer’s disease. Adv Exp Med Biol. https://doi.org/10.1007/978-981-13-1370-7_6
Normandin L, Hazell AS (2002) Manganese neurotoxicity: an update of pathophysiologic mechanisms. Metab Brain Dis 17:375–387
Notarachille G et al (2014) Heavy metals toxicity: effect of cadmium ions on amyloid beta protein 1–42. Possible implications for Alzheimer’s disease. BioMetals 27:371–388
Opazo C et al (2002) Metalloenzyme-like activity of Alzheimer’s disease β-amyloid. J Biol Chem 277:40302–40308
Ozcankaya R, Delibas N (2002) Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J 43:28–32
Paglia G et al (2016) Distinctive pattern of serum elements during the progression of Alzheimer’s disease. Sci Rep 6:22769
Pakzad D et al (2021) Risk of neurodegenerative disease due to tau phosphorylation changes and arsenic exposure via drinking water. Toxicology Research 10:325–333
Park JD et al (2008) Tissue distribution of manganese in iron-sufficient or iron-deficient rats after stainless steel welding-fume exposure. Inhalation Toxicol 19:563–572
Park JH et al (2014) Elevated serum copper and ceruloplasmin levels in Alzheimer’s disease. Asia Pac Psychiatry 6:38–45
Park JH et al (2014) Serum trace metal levels in Alzheimer’s disease and normal control groups. Am J Alzheimers Dis Other Demen 29:76–83
Peng Q et al (2017) Cadmium and Alzheimer’s disease mortality in U.S. adults: updated evidence with a urinary biomarker and extended follow-up time. Environ Res 157:44–51
Pohl HR et al (2011) Metal ions affecting the neurological system. Met Ions Life Sci 8:247–62
Porsteinsson AP et al (2021) Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prevent Alzheimer Dis. https://doi.org/10.14283/jpad.2021.23
Pu Z et al (2017) Oxidative stress markers and metal ions are correlated with cognitive function in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 32:353–359
Qing Y et al (2021) Urinary cadmium in relation to bone damage: cadmium exposure threshold dose and health-based guidance value estimation. Ecotoxicol Environ Saf 226:1–10
Qing Y et al (2021) Dose-response evaluation of urinary cadmium and kidney injury biomarkers in Chinese residents and dietary limit standards. Environ Health 20:1–9
Rahman M et al (2021) Exposure to environmental arsenic and emerging risk of Alzheimer’s disease: perspective mechanisms, management strategy, and future directions. Toxics 9:188
Religa D et al (2006) Elevated cortical zinc in Alzheimer disease. Neurology 67:69–75
Rembach A et al (2013) Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer’s disease. J Alzheimers Dis 34:171–182
Rembach A et al (2014) Decreased serum zinc is an effect of ageing and not Alzheimer’s disease. Metallomics 6:1216–1219
Rita Cardoso B et al (2014) Selenium status in elderly: relation to cognitive decline. J Trace Elem Med Biol 28:422–426
Ritchie CW et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (Clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 60:1685–1691
Rondeau V et al (2009) Aluminum and silica in drinking water and the risk of Alzheimer’s disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol 169:489–496
Rozzini L et al (2018) Serum non-ceruloplasmin non-albumin copper elevation in mild cognitive impairment and dementia due to Alzheimer’s disease: a case control study. J Alzheimers Dis 61:907–912
Salustri C et al (2010) Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clin Neurophysiol 121:502–507
Sanders T et al (2009) Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health 24:15–45
Schomburg L (2022) Selenoprotein P—selenium transport protein, enzyme and biomarker of selenium status. Free Radical Biol Med 191:150–163
Sensi SL et al (2018) Copper and zinc dysregulation in Alzheimer’s disease. Trends Pharmacol Sci 39:1049–1063
Shah RC et al (2011) Hemoglobin level in older persons and incident Alzheimer disease: prospective cohort analysis. Neurology 77:219–226
Sharma S et al (2020) Effect of environmental toxicants on neuronal functions. Environ Sci Pollut Res 27:44906–44921
Shere S et al (2018) Lower levels of serum copper in patients with Alzheimer’s dementia: a controlled study from India. Asian J Psychiatr 32:73–74
Singh NK et al (2014) Polymorphism in cytochrome P450 2D6, glutathione S-transferases Pi 1 genes, and organochlorine pesticides in alzheimer disease: a case-control study in North Indian population. J Geriatr Psychiatry Neurol 27:119–127
Sirivarasai J et al (2021) Role of MT1A polymorphism and environmental mercury exposure on the montreal cognitive assessment (MoCA). Neuropsychiatr Dis Treat 17:2429–2439
Smorgon C et al (2004) Trace elements and cognitive impairment: an elderly cohort study. Arch Gerontol Geriatr Suppl 38:393–402
Socha K et al (2021) Dietary habits, selenium, copper, zinc and total antioxidant status in serum in relation to cognitive functions of patients with Alzheimer’s disease. Nutrients 13:287
Sola E et al (2023) Cadmium-promoted thyroid hormones disruption mediates ROS, inflammation, Aβ and Tau proteins production, gliosis, spongiosis and neurodegeneration in rat basal forebrain. Chem Biol Interact 375:110428
Solovyev N (2019) Selenoprotein P and its potential role in Alzheimer’s disease. Hormones 19:73–79
Spitznagel BD et al (2023) Acute manganese exposure impairs glutamatergic function in a young mouse model of Alzheimer’s disease. Neurotoxicology 95:1–11
Squitti R et al (2006) Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF -amyloid, and h-tau. Neurology 67:76–82
Squitti R et al (2011) Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis 23:239–248
Squitti R et al (2014) Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. Ann Neurol 75:574–580
Squitti R et al (2002) Elevation of serum copper levels in Alzheimer’s disease. Neurology 59:1153–1161
Squitti R et al (2019) Copper involvement in glutamatergic transmission in physiology and disease as revealed by magnetoencephalography/electroencephalography (MEG/EEG) studies. Aging Clin Exp Res 33:2023–2026
Squitti R et al (2005) Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64:1040–1046
Squitti R et al (2013) Metal-score as a potential non-invasive diagnostic test for Alzheimer’s disease. Curr Alzheimer Res 10:191–198
Squitti R et al (2013) ATP7B variants as modulators of copper dyshomeostasis in Alzheimer’s disease. Neuromolecular Med 15:515–522
Squitti R et al (2002) d-penicillamine reduces serum oxidative stress in Alzheimer’s disease patients. Eur J Clin Invest 32:51–59
Squitti R et al (2010) Ceruloplasmin/transferrin ratio changes in Alzheimer’s disease. Int J Alzheimers Dis 2011:231595
Squitti R et al (2007) ‘Free’ copper in serum of Alzheimer’s disease patients correlates with markers of liver function. J Neural Transm 114:1589–1594
Stahl T et al (2017) Migration of aluminum from food contact materials to food—a health risk for consumers? Part I of III: exposure to aluminum, release of aluminum, tolerable weekly intake (TWI), toxicological effects of aluminum, study design, and methods. Environ Sci Eur 29:1–8
Sternberg Z et al (2017) Serum hepcidin levels, iron dyshomeostasis and cognitive loss in alzheimer’s disease. Aging Dis 8:215–227
Sun R et al (2022) Zinc in cognitive impairment and aging. Biomolecules 12:1000
Takahashi A (2022) Role of zinc and copper in erythropoiesis in patients on hemodialysis. J Ren Nutr 32:650–657
Tao Y et al (2014) Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J Alzheimers Dis 42:679–690
Teixeira FB et al (2019) Neurochemical dysfunction in motor cortex and hippocampus impairs the behavioral performance of rats chronically exposed to inorganic mercury. J Trace Elem Med Biol 52:143–150
Tomljenovic L (2011) Aluminum and Alzheimer’s disease: after a century of controversy, is there a plausible link? J Alzheimers Dis 23:567–598
Tsinovoi CL et al (2018) Arsenic exposure in relation to ischemic stroke. Stroke 49:19–26
Tyczyńska M et al (2024) Trace elements in Alzheimer’s disease and dementia: the current state of knowledge. J Clin Med 13:1–23
Vasefi M et al (2020) Environmental toxins and Alzheimer’s disease progression. Neurochem Int 141:104852
Veronese N et al (2015) Magnesium status in Alzheimer’s Disease. Am J Alzheimer Dis Other Dementiasr 31:208–213
Viswanathan A et al (2009) Vascular risk factors and dementia. Neurology 72:368–374
Volpe SL (2013) Magnesium in disease prevention and overall health. Adv Nutr 4:378–383
Vural H et al (2010) Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer’s disease. J Trace Elem Med Biol 24:169–173
Wang H et al (2012) Immunogold labeling and X-ray fluorescence microscopy reveal enrichment ratios of Cu and Zn, metabolism of APP and amyloid-β plaque formation in a mouse model of Alzheimer’s disease. Metallomics 4:1113–1118
Wang Z et al (2016) Chronic exposure to aluminum and risk of Alzheimer’s disease: a meta-analysis. Neurosci Lett 610:200–206
Ward RJ et al (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13:1045–1060
Weil M (2005) Blood mercury levels and neurobehavioral function. JAMA 293:1875–1882
Xie J et al (2023) Developmental Pb exposure increases AD risk via altered intracellular Ca2+ homeostasis in hiPSC-derived cortical neurons. J Biol Chem 299:105023
Xu L et al (2018) Circulatory levels of toxic metals (aluminum, cadmium, mercury, lead) in patients with Alzheimer’s disease: a quantitative meta-analysis and systematic review. J Alzheimers Dis 62:361–372
Yadav J et al (2021) Metals toxicity and its correlation with the gene expression in Alzheimer’s disease. Mol Biol Rep 48:3245–3252
Yang YW et al (2018) Risk of Alzheimer’s disease with metal concentrations in whole blood and urine: a case-control study using propensity score matching. Toxicol Appl Pharmacol 356:8–14
Zappasodi F et al (2008) An observational study on the influence of the APOE-ε4 allele on the correlation between ‘free’ copper toxicosis and EEG activity in Alzheimer disease. Brain Res 1215:183–189
Zhao M et al (2020) Multiple exposure pathways and urinary chromium in residents exposed to chromium. Environ Int 141:105753
Zheng Z et al (2010) Altered microglial copper homeostasis in a mouse model of Alzheimer’s disease. J Neurochem 114:1630–1638
Funding
This work was supported by the Shanghai Sailing Program (No. 21YF1418500), the Shanghai Chenguang Program (No. 21CGA70), the three-year action plan for strengthening the construction of the public health system in Shanghai (No. GWVI-11.2-YQ12), the Natural Science Foundation of Shanghai (No. 21ZR1428400) and the Health Science and Technology Project of Shanghai Pudong New Area Health Commission (No. PW2021A-69). Additionally, thanks to innovative team of intelligent inspection and active health (ITIH) for their support of this study.
Author information
Authors and Affiliations
Contributions
Author contributions: Ying Qing: Conceptualization, Methodology, Data curation, Writing-original draft, Writing-review & editing; Jianheng Zheng: Methodology, Data Curation, Formal analysis; Meng Qin: Writing-review & editing, Data Curation; Xiufen Liu: Data Curation; Zhao Dai: Data Curation; Xinyue Xu: Data Curation; Yingyi Luo: Software; Shichun Li: Visualization; Liqiang Wang: Data Curation; Shuyu Yang: Writing—Review & Editing; Jun Du: Supervision; Ying Lu: Project administration, Funding acquisition; Yanfei Li: Supervision, Project administration, Funding acquisition. All authors reviewed the manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Qing, Y., Zheng, J., Qin, M. et al. Circulatory trace element variations in Alzheimer’s disease: a systematic review and meta-analysis. Environ Sci Eur 36, 148 (2024). https://doi.org/10.1186/s12302-024-00980-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12302-024-00980-z